Are second generation antipsychotics a distinct class?

Journal of Psychiatric Practice

Volumn 14, Issue 4, 2008, Pages 225-231

  Bonham, Caroline ^a   Abbott, Christopher ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antipsychotics; Atypical antipsychotic; Efficacy; Extrapyramidal symptoms; First generation antipsychotic; Negative symptoms; Neurocognitive effects; Quality of life; Schizophrenia; Second generation antipsychotic

Indexed keywords

AMOXAPINE; ARIPIPRAZOLE; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; EXTRAPYRAMIDAL SYNDROME; PSYCHOLOGICAL ASPECT; REVIEW;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; COGNITION DISORDERS; HALOPERIDOL; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 58149183065     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000327312.04153.da     Document Type: Article

References (59)

1. Cole JO. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964;10:246-61.
2. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004;4:53-7.
3. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60:22-3.
4. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
5. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-84.
6. Meltzer HY. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18-27.
7. 2 receptor explain the action of the atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-9.
8. Westerink BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 2002;455:1-18.
9. 2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991-2001.
10. Kane J. Pharmacological treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408.
11. Meltzer H, McQurk S. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
12. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006 Oct 18;(4): CD003082.
13. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: A systematic overview and meta-regression analysis. BMJ 2000;321: 1371-76.
14. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
15. Geddes J, Harrison P, Freemantle N. New generation versus conventional antipsychotics. Lancet 2003;362:404-5.
16. Davis JM, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 2003; 60:553-64.
17. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361:1581-9.
18. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. N Engl J Med 1997;337:809-15.
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
20. Lieberman JA. Comparative effectiveness of antipsychotic drugs: A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006;63:1069-72.
21. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
22. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9.
23. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
24. Meltzer H. An atypical compound by any other name is still a ... Psychopharmacology 2000;148:16-9.
25. Barnes TRE. A rating scale for drug-induced akathesia. Br J Psychiatry 1989;154:672-6.
26. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19.
27. Chouinard G, Ross-Chouinard A, Annable L, et al. Extra-pyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7:234.
28. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 534-7.
29. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16: 38-44.
30. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
31. Cooper SJ, Tweed J, Raniqalla J, et al. A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scan 2000;101:218-25, 37.
32. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
33. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment resistant schizophrenia: Results of a multicenter, randomized, double blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213-23.
34. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
35. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
36. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88:395-402.
37. Apiquian R, Fresan A, Ulloa R, et al. Amoxapine as an atypical antipsychotic: A comparative study vs risperidone. Neuropsychopharmacology 2005;30:2236-44.
38. Kane JM, Khanna S, Rjadhyasksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21:21-8.
39. Kostakoglu E, Alptekin K, Kivicik BB, et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine. Errata, European Neuropsychopharmacology 2000;10(suppl 3):2000 (abstract).
40. Naukkarinen H, Rimon R, Katila H, et al. Olanzapine and perphenazine in schizophrenia. Schizophr Res 2000;41:190 (abstract).
41. Mraz K, Gogus A, Tunca Z, et al. Olanzapine versus chlorpromazine in Turkey. Schizophr Res (Abstracts of the Winter Workshop on Schizophrenia: Feb 2000; Davos; Switzerland).
42. Loza N, El-Dosoky AM, Okasha TA, et al. Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol 1999;9:S291 (abstract).
43. Fitzgerald PB, Filia S, de Castella A, et al. Amoxapine in schizophrenia: A negative double-blind trial. J Clin Psychopharmacol 2004;24:448-9.
44. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8.
45. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161: 414-25.
46. Morgenstern G, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: Results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 1993:50:723-33.
47. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33-43.
48. Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 2003;64:524-31.
49. Schillevoort I, Herings RMC, Hugenholtz GWK, et al. Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: A case control study. Pharm World Sci 2005;27: 285-9.
50. Schillevoort I, de Boer A, Herings RMC, et al. Antipsychotic-induced extrapyramidal syndromes: Risperidone compared with low- and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol 2001;57:327-31.
51. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability - Are patients better off? Can J Psychiatry 2004;49:297-302
52. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-93.
53. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 1999; 25:201-222.
54. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64: 633-47.
55. Leucht C, Kitzmantle N, Chua L, et al. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev 2008 23;(1):CD004278.
56. Gerlach J. Atypical antipsychotics: An inspiring but confusing concept. Psychopharmacology (Berl) 2000;148:1-2.
57. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60:5-14.
58. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
59. Aparasu RR, Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006;57:1693.